Skip to main content
Erschienen in: Lung 6/2013

01.12.2013

Relationship Between Quantitative CT Metrics and Pulmonary Function in Combined Pulmonary Fibrosis and Emphysema

verfasst von: Katsutoshi Ando, Mitsuaki Sekiya, Kazunori Tobino, Kazuhisa Takahashi

Erschienen in: Lung | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Combined pulmonary fibrosis and emphysema (CPFE) is increasingly recognized, as current reports of its clinical features show. To determine CPFE’s physiologic and radiologic features, we conducted quantitative assessment of computed tomography scans to compare with those of chronic obstructive pulmonary disease (COPD).

Methods

In 23 patients with CPFE and 42 patients with COPD, we measured the extent of emphysema (LAA %), parenchymal density, and total cross-sectional areas of pulmonary vessels smaller than 5 mm2 (%CSA <5) and 5–10 mm2 (%CSA 5–10).

Results

For CPFE, airflow was better, but diffusing capacity for carbon monoxide (DLCO) was worse than for COPD, whereas LAA % was similar for both groups. The %CSA <5 was greater but %CSA5–10 was less in CPFE than COPD. COPD involved a negative correlation between DLCO and LAA % at all lung sites; those factors correlated for CPFE only in the upper lobe (r = −0.535). In contrast, CPFE had a negative correlation between DLCO and parenchymal density in lower lobes (r = −0.453), but COPD showed no correlation in any such sections. In CPFE, no correlation was apparent between LAA in upper lobes and parenchymal density in lower lobes. The annual rate of FVC decline (−169.26 ml/year) in CPFE patients correlated with parenchymal density (r = −0.714).

Conclusions

In CPFE, fibrosis and emphysema apparently existed independently, but both correlate with and likely contribute to the disproportionate reduction in gas exchange. Our study also suggested that pulmonary fibrotic changes may be more important contributors than emphysema for disease progression.
Literatur
1.
Zurück zum Zitat Cottin V, Nunes H, Brillet PY et al (2005) Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 26:586–593CrossRefPubMed Cottin V, Nunes H, Brillet PY et al (2005) Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 26:586–593CrossRefPubMed
2.
Zurück zum Zitat Mejía M, Carrillo G, Rojas-Serrano J et al (2009) Idiopathic pulmonary fibrosis and emphysema decreased survival associated with severe pulmonary arterial hypertension. Chest 136:10–15CrossRefPubMed Mejía M, Carrillo G, Rojas-Serrano J et al (2009) Idiopathic pulmonary fibrosis and emphysema decreased survival associated with severe pulmonary arterial hypertension. Chest 136:10–15CrossRefPubMed
3.
Zurück zum Zitat Kitaguchi Y, Fujimoto K, Hanaoka M et al (2010) Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology 15:265–271CrossRefPubMed Kitaguchi Y, Fujimoto K, Hanaoka M et al (2010) Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology 15:265–271CrossRefPubMed
4.
Zurück zum Zitat Kurashima K, Takayanagi N, Tsuchiya N et al (2010) The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis. Respirology 15:843–848CrossRefPubMed Kurashima K, Takayanagi N, Tsuchiya N et al (2010) The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis. Respirology 15:843–848CrossRefPubMed
5.
Zurück zum Zitat Chiba S, Ohta H, Abe K et al (2012) The diagnostic value of the interstitial biomarkers KL-6 and SP-D for the degree of fibrosis in combined pulmonary fibrosis and emphysema. Pulm Med 492960 Chiba S, Ohta H, Abe K et al (2012) The diagnostic value of the interstitial biomarkers KL-6 and SP-D for the degree of fibrosis in combined pulmonary fibrosis and emphysema. Pulm Med 492960
6.
Zurück zum Zitat Austin JH, Muller NL, Colman N et al (1999) Diagnosis of disease of the chest. WB Saunders, Philadelphia, pp 2168–2263 Austin JH, Muller NL, Colman N et al (1999) Diagnosis of disease of the chest. WB Saunders, Philadelphia, pp 2168–2263
7.
Zurück zum Zitat Thurlbeck WM, Muller NL (1994) Emphysema: definition, imaging, and quantification. AJR Am J Roentgenol 163:1017–1025CrossRefPubMed Thurlbeck WM, Muller NL (1994) Emphysema: definition, imaging, and quantification. AJR Am J Roentgenol 163:1017–1025CrossRefPubMed
8.
Zurück zum Zitat Sakai N, Mishima M, Nishimura K, Itoh H, Kuno K (1994) An automated method to assess the distribution of low attenuation areas on chest CT scans in chronic pulmonary emphysema patients. Chest 106:1319–1325CrossRefPubMed Sakai N, Mishima M, Nishimura K, Itoh H, Kuno K (1994) An automated method to assess the distribution of low attenuation areas on chest CT scans in chronic pulmonary emphysema patients. Chest 106:1319–1325CrossRefPubMed
9.
Zurück zum Zitat Mishima M, Hirai T, Itoh H et al (1999) Complexity of terminal airspace geometry assessed by lung computed tomography in normal subjects and patients with chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 96:8829–8834PubMedCentralCrossRefPubMed Mishima M, Hirai T, Itoh H et al (1999) Complexity of terminal airspace geometry assessed by lung computed tomography in normal subjects and patients with chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 96:8829–8834PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Nakano Y, Sakai H, Muro S et al (1999) Comparison of low attenuation areas on computed tomographic scans between inner and outer segments of the lung in patients with chronic obstructive pulmonary disease: incidence and contribution to lung function. Thorax 54:384–389PubMedCentralCrossRefPubMed Nakano Y, Sakai H, Muro S et al (1999) Comparison of low attenuation areas on computed tomographic scans between inner and outer segments of the lung in patients with chronic obstructive pulmonary disease: incidence and contribution to lung function. Thorax 54:384–389PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Matsuoka S, Washko GR, Yamashiro T et al (2010) Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema. Am J Respir Crit Care Med 181:218–225PubMedCentralCrossRefPubMed Matsuoka S, Washko GR, Yamashiro T et al (2010) Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema. Am J Respir Crit Care Med 181:218–225PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Matsuoka S, Washko GR, Dransfield MT et al (2010) Quantitative CT measurement of cross-sectional area of small pulmonary vessel in COPD: correlations with emphysema and airflow limitation. Acad Radiol 17:93–99PubMedCentralCrossRefPubMed Matsuoka S, Washko GR, Dransfield MT et al (2010) Quantitative CT measurement of cross-sectional area of small pulmonary vessel in COPD: correlations with emphysema and airflow limitation. Acad Radiol 17:93–99PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat Uejima I, Matsuoka S, Yamashiro T, Yagihashi K, Kurihara Y, Nakajima Y (2011) Quantitative computed tomographic measurement of a cross-sectional area of a small pulmonary vessel in nonsmokers without airflow limitation. Jpn J Radiol 29:251–255CrossRefPubMed Uejima I, Matsuoka S, Yamashiro T, Yagihashi K, Kurihara Y, Nakajima Y (2011) Quantitative computed tomographic measurement of a cross-sectional area of a small pulmonary vessel in nonsmokers without airflow limitation. Jpn J Radiol 29:251–255CrossRefPubMed
14.
Zurück zum Zitat Ando K, Tobino K, Kurihara M et al (2012) Quantitative CT analysis of small pulmonary vessels in lymphangioleiomyomatosis. Eur J Radiol 81:3925–3930CrossRefPubMed Ando K, Tobino K, Kurihara M et al (2012) Quantitative CT analysis of small pulmonary vessels in lymphangioleiomyomatosis. Eur J Radiol 81:3925–3930CrossRefPubMed
15.
Zurück zum Zitat Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2011) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Heart, Lung and Blood Institute, World Health Organization, Bethesda Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2011) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Heart, Lung and Blood Institute, World Health Organization, Bethesda
16.
Zurück zum Zitat Sharp DS (1993) Reference values for lung function in the Japanese: recording of normal lung function from 11 institutes in Japan. Jpn J Thoracic Dis 31:421–427 Sharp DS (1993) Reference values for lung function in the Japanese: recording of normal lung function from 11 institutes in Japan. Jpn J Thoracic Dis 31:421–427
17.
Zurück zum Zitat Demedts M, Behr J, Buhl R et al (2005) High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353:2229–2242CrossRefPubMed Demedts M, Behr J, Buhl R et al (2005) High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353:2229–2242CrossRefPubMed
18.
Zurück zum Zitat Taniguch H, Ebina M, Kondoh Y et al (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35:821–829CrossRef Taniguch H, Ebina M, Kondoh Y et al (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35:821–829CrossRef
19.
Zurück zum Zitat Richeldi L, Costabel U, Selman M et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087CrossRefPubMed Richeldi L, Costabel U, Selman M et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087CrossRefPubMed
20.
Zurück zum Zitat Santos S, Peinado VI, Ramirez J et al (2003) Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167:1250–1256CrossRefPubMed Santos S, Peinado VI, Ramirez J et al (2003) Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167:1250–1256CrossRefPubMed
21.
Zurück zum Zitat Barr RG, Mesia-Vela S, Austin JH et al (2007) Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the emphysema and cancer action project (EMCAP) Study. Am J Respir Crit Care Med 176:1200–1207PubMedCentralCrossRefPubMed Barr RG, Mesia-Vela S, Austin JH et al (2007) Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the emphysema and cancer action project (EMCAP) Study. Am J Respir Crit Care Med 176:1200–1207PubMedCentralCrossRefPubMed
22.
Zurück zum Zitat Farkas L, Gauldie J, Voelkel NF et al (2011) Pulmonary hypertension and idiopathic pulmonary fibrosis. Am J Cell Mol Biol 45:1–15CrossRef Farkas L, Gauldie J, Voelkel NF et al (2011) Pulmonary hypertension and idiopathic pulmonary fibrosis. Am J Cell Mol Biol 45:1–15CrossRef
23.
Zurück zum Zitat Judge EP, Fabre A, Adamali HI et al (2012) Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J 40:93–100CrossRefPubMed Judge EP, Fabre A, Adamali HI et al (2012) Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J 40:93–100CrossRefPubMed
24.
Zurück zum Zitat Ebina M, Shimizukawa M, Shibata et al (2004) Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 169:1203–1208CrossRefPubMed Ebina M, Shimizukawa M, Shibata et al (2004) Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 169:1203–1208CrossRefPubMed
25.
Zurück zum Zitat Simler NR, Brenchley PE, Horrocks AW et al (2004) Angiogenic cytokines in patients in patients with idiopathic pulmonary fibrosis. Thorax 59:581–585PubMedCentralCrossRefPubMed Simler NR, Brenchley PE, Horrocks AW et al (2004) Angiogenic cytokines in patients in patients with idiopathic pulmonary fibrosis. Thorax 59:581–585PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat Cosgrove GP, Brown KK, Schiemann WP et al (2004) Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 170:242–251CrossRefPubMed Cosgrove GP, Brown KK, Schiemann WP et al (2004) Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 170:242–251CrossRefPubMed
Metadaten
Titel
Relationship Between Quantitative CT Metrics and Pulmonary Function in Combined Pulmonary Fibrosis and Emphysema
verfasst von
Katsutoshi Ando
Mitsuaki Sekiya
Kazunori Tobino
Kazuhisa Takahashi
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Lung / Ausgabe 6/2013
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-013-9513-1

Weitere Artikel der Ausgabe 6/2013

Lung 6/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.